Carolyn Bertozzi Buys Shares of OmniAb, Inc. (OABI)

Carolyn Bertozzi recently bought 20,000 shares of OmniAb, Inc. (NasdaqGM: OABI) on June 17, 2026. This transaction was not part of a pre-planned trading program. On Friday, OmniAb's shares traded around $2.34.

Insider Buying and Selling at OmniAb, Inc.

On June 17, 2026, Carolyn Bertozzi acquired 20,000 shares of OmniAb, Inc. This purchase was executed without a pre-planned trading arrangement. Other insiders involved in transactions on the same day include Jennifer Cochran, who bought 40,000 shares and sold 20,000 shares, and John Higgins, who purchased 20,000 shares.

Other Institutional Activity in OmniAb, Inc.

Various institutional investors have adjusted their positions in OmniAb, Inc. BlackRock, Inc. added 41,900 shares, bringing its total holdings to 8,106,881 shares, valued at approximately $12.7 million. Geode Capital Management, LLC increased its stake by 202,887 shares, ending with 2,925,579 shares worth about $4.6 million. Vanguard Capital Management LLC opened a new position with 3,993,652 shares, valued at approximately $6.3 million. Meanwhile, Cadian Capital Management, LP reduced its holdings by 277,825 shares, now holding 4,157,129 shares valued at around $6.5 million.

OmniAb, Inc. Stock Down 47.7%

OmniAb, Inc. trades on the NasdaqGM under the ticker OABI. As of Friday, shares were priced near $2.34. The company has a market capitalization of approximately $339.2 million. Although it isn't currently profitable, it features a forward P/E ratio of -7.26 and a beta of 1.146, indicating some volatility relative to the market. The stock's 52-week range spans from $1.30 to $2.79, with a 50-day moving average of $1.97 and a 200-day moving average of $1.80.

Analysts Set New Price Targets

Analysts have shown interest in OmniAb, Inc., with several firms maintaining a positive outlook. On August 7, 2025, RBC Capital maintained a 'buy' rating with a price target of $3.0. Benchmark reiterated its 'buy' rating with a target of $6.0 on May 12, 2025. HC Wainwright & Co. has consistently reiterated a 'buy' rating, setting a target of $11.0 on March 19, 2025. The consensus target price among analysts is approximately $7.33, based on six opinions.

About OmniAb, Inc.

OmniAb, Inc. is a biotechnology company headquartered in Emeryville, California. It specializes in licensing discovery research technology to pharmaceutical and biotech companies, as well as academic institutions, to aid in the discovery of new therapeutics. The company uses its OmniAb platform to create and screen diverse antibody repertoires, helping partners develop drugs by identifying optimal antibodies. OmniAb's technology includes genetically engineered transgenic animals, such as OmniRat, OmniChicken, and OmniMouse, which generate human-sequence antibodies. Founded in 2012, the company is led by CEO Matthew W. Foehr and employs 89 people.

Bottom Line

Carolyn Bertozzi's recent purchase of OmniAb shares highlights ongoing interest in the company's potential. Investors keep an eye on such insider activity for insights into company prospects. Although OmniAb is not currently profitable, its innovative technology in the biotechnology sector makes it a company to watch. Keep in mind that insider transactions provide historical data and may not indicate future performance.